SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-21-031718
Filing Date
2021-06-09
Accepted
2021-06-09 17:06:00
Documents
6
Period of Report
2021-06-09

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea142416-6k_purplebiotech.htm 6-K 28306
2 OPEN MARKET SALE AGREEMENTSM, DATED AS OF JUNE 9, 2021, BY AND BETWEEN THE COMPA ea142416ex1-1_purplebiotech.htm EX-1.1 265205
3 OPINION OF ABZ LAW OFFICE REGARDING THE VALIDITY OF THE ORDINARY SHARES ea142416ex5-1_purplebiotech.htm EX-5.1 18802
4 OPINION OF HAYNES AND BOONE, LLP ea142416ex5-2_purplebiotech.htm EX-5.2 8540
5 GRAPHIC ex5-1_001.jpg GRAPHIC 43177
6 GRAPHIC ex5-1_002.jpg GRAPHIC 47546
  Complete submission text file 0001213900-21-031718.txt   447314
Mailing Address 4 OPPENHEIMER STREET SCIENCE PARK REHOVOT L3 7670104
Business Address 4 OPPENHEIMER STREET SCIENCE PARK REHOVOT L3 7670104 97239333121
PURPLE BIOTECH LTD. (Filer) CIK: 0001614744 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-37643 | Film No.: 211005892
SIC: 2834 Pharmaceutical Preparations